Get notified when TNGX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution of $24.10 Per Share (new) — New investors pay $30.00 per share for stock with a net tangible book value of only $5.90, resulting in substantial immediate dilution.
- No Clinical Trial Supply Agreement or Commercial Supply Agreement For Vopimetostat (new) — The company's lead program depends on third-party collaborators for drug supply, and it has not secured agreements for the planned Phase 3 trial or commercialization.
Tango Therapeutics prices $600M offering: 18.17M shares at $30.00 plus pre-funded warrants
Filed June 10, 2026 · ~1 min read
Key Changes
-
high
Tango Therapeutics is offering 18,166,667 shares at $30.00 per share and pre-funded warrants for 1,833,395 shares at $29.999, totaling $600,000,026.61 before expenses.
The Offering verify on EDGAR → -
high
The company will receive net proceeds of approximately $566.5 million (or $651.6 million if underwriters fully exercise their option), after underwriting discounts and expenses.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $24.10 per share: they pay $30.00 for shares with an as-adjusted net tangible book value of $5.90.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (NTSK 10-Q) is open in full — no account needed.
Partner
Trade TNGX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify